Treatment selection and real‐world analysis of immunotherapy with or without chemotherapy in PD‐L1‐high metastatic non‐small cell lung cancer

Documenti analoghi

• Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme
  di: Marliese Alexander, et al.
  Pubblicazione: (2024)
• Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete metabolic response or toxicities
  di: Nur Sakinah Zulkifli, et al.
  Pubblicazione: (2026)
• Neoadjuvant chemotherapy in breast cancer: a retrospective pathway assessment in a regional cancer centre
  di: Lachlan Fitzpatrick, et al.
  Pubblicazione: (2024)
• Opportunistic assessment of steatotic liver disease in lung cancer screening eligible individuals
  di: Jakob Weiss, et al.
  Pubblicazione: (2025)
• Improving the timeliness of care for regional lung cancer patients through the implementation of a web‐based lung cancer referral pathway
  di: Zulfiquer Otty, et al.
  Pubblicazione: (2025)